ClinicalTrials.Veeva

Menu

Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis

University Health Network, Toronto logo

University Health Network, Toronto

Status and phase

Terminated
Phase 2

Conditions

Mild or Moderate Anaemia
Ulcerative Colitis
Crohn's Disease

Treatments

Drug: Iron supplement 300-600 mg/day
Drug: Vitamin E 800IU

Study type

Interventional

Funder types

Other

Identifiers

NCT00152841
02-0289-E

Details and patient eligibility

About

Hypothesis:In patients with ulcerative colitis and Crohn's disease diagnosed with mild or moderate anaemia:

  1. iron supplementation will increase disease activity and oxidative stress
  2. the addition of antioxidant vitamin will reduce this detrimental effect

Full description

To maintain site/extent of disease and medication consistent among groups, the design is a double blind crossover placebo-controlled trial.

  1. If mild anaemia, patients are randomized to 300 mg of ferrous fumarate or placebo for 4 weeks followed by 2 weeks of washout period after which patients will crossover the opposite treatments for another 4 weeks.
  2. If moderate anaemia, patients will receive 600 mg of ferrous fumarate for 10 weeks. They are randomized to either vitamin E (800 IU) or placebo for 4 weeks followed by 2 weeks of washout period after which patients will crossover the opposite treatments for another 4 weeks

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • > 18 years old
  • diagnosed with inflammatory Bowel Disease (ulcerative colitis and Crohn's disease)
  • with mild or moderate anaemia

Exclusion criteria

  • not diagnosed with bowel obstruction
  • not diagnosed with short bowel syndrome
  • not taking iron supplement or antioxidant vitamins and minerals

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems